Identification of a tumor-associated mutant form of the NF-κB RelA gene with reduced DNA-binding and transactivating activities

Dino Trecca, Luisa Guerrini, Nicola Stefano Fracchiolla, Mauro Pomati, Luca Baldini, Anna Teresa Maiolo, Antonino Neri

Research output: Contribution to journalArticle

Abstract

Alterations of NF-κB family members have been found to be associated with various forms of lymphoid malignancies. In order to determine whether alterations of the RelA gene are involved in lymphomagenesis, we analysed a large and representative panel (200 cases) of such tumors. Southern blot analysis did not reveal any rearrangements or locus amplification, suggesting that structural alterations of the RelA gene may represent rare events in lymphoid neoplasia. By means of PCR-SSCP analysis, we were able to identify a single point mutation leading to amino acid substitution (codon 494, Glu-Asp) in the transactivating (TA) domain in one case of multiple myeloma. The mutated allele was expressed in the pathological bone marrow sample but not in the peripheral blood cells of the patient. We demonstrate that the RelA protein carrying this specific mutation (called RelA(494D)) has less transactivating ability than the normal RelA protein. Interestingly, the mutated protein has a lower affinity for κB binding sites both as a homodimer or in association with the NFKB1/p50 subunit. Transfection experiments using a Gal4-RelA(494D) fusion protein indicated that the mutation does not alter the intrinsic transactivating ability of the TA domain of RelA. Furthermore, in vitro translated RelA(494D) is able to dimerize efficiently with other NF-κB members, such as p50, cREL and IκBα. Our data therefore suggest that this mutation may alter the specific structural conformation needed for the DNA interaction of RelA, and provide insights into the amino acid sequences involved in mediating the biological activities of RelA.

Original languageEnglish
Pages (from-to)791-799
Number of pages9
JournalOncogene
Volume14
Issue number7
Publication statusPublished - 1997

Fingerprint

Aptitude
DNA
Mutation
Genes
Neoplasms
Proteins
Nucleic Acid Conformation
Single-Stranded Conformational Polymorphism
Amino Acid Substitution
Southern Blotting
Multiple Myeloma
Point Mutation
Codon
Transfection
Amino Acid Sequence
Blood Cells
Bone Marrow
Alleles
Binding Sites
Polymerase Chain Reaction

Keywords

  • Lymphoid malignancies
  • NF-κB
  • RelA
  • Transcriptional activity

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Identification of a tumor-associated mutant form of the NF-κB RelA gene with reduced DNA-binding and transactivating activities. / Trecca, Dino; Guerrini, Luisa; Fracchiolla, Nicola Stefano; Pomati, Mauro; Baldini, Luca; Maiolo, Anna Teresa; Neri, Antonino.

In: Oncogene, Vol. 14, No. 7, 1997, p. 791-799.

Research output: Contribution to journalArticle

@article{8a23c82fb4ce44e9a7ef43c708332599,
title = "Identification of a tumor-associated mutant form of the NF-κB RelA gene with reduced DNA-binding and transactivating activities",
abstract = "Alterations of NF-κB family members have been found to be associated with various forms of lymphoid malignancies. In order to determine whether alterations of the RelA gene are involved in lymphomagenesis, we analysed a large and representative panel (200 cases) of such tumors. Southern blot analysis did not reveal any rearrangements or locus amplification, suggesting that structural alterations of the RelA gene may represent rare events in lymphoid neoplasia. By means of PCR-SSCP analysis, we were able to identify a single point mutation leading to amino acid substitution (codon 494, Glu-Asp) in the transactivating (TA) domain in one case of multiple myeloma. The mutated allele was expressed in the pathological bone marrow sample but not in the peripheral blood cells of the patient. We demonstrate that the RelA protein carrying this specific mutation (called RelA(494D)) has less transactivating ability than the normal RelA protein. Interestingly, the mutated protein has a lower affinity for κB binding sites both as a homodimer or in association with the NFKB1/p50 subunit. Transfection experiments using a Gal4-RelA(494D) fusion protein indicated that the mutation does not alter the intrinsic transactivating ability of the TA domain of RelA. Furthermore, in vitro translated RelA(494D) is able to dimerize efficiently with other NF-κB members, such as p50, cREL and IκBα. Our data therefore suggest that this mutation may alter the specific structural conformation needed for the DNA interaction of RelA, and provide insights into the amino acid sequences involved in mediating the biological activities of RelA.",
keywords = "Lymphoid malignancies, NF-κB, RelA, Transcriptional activity",
author = "Dino Trecca and Luisa Guerrini and Fracchiolla, {Nicola Stefano} and Mauro Pomati and Luca Baldini and Maiolo, {Anna Teresa} and Antonino Neri",
year = "1997",
language = "English",
volume = "14",
pages = "791--799",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Identification of a tumor-associated mutant form of the NF-κB RelA gene with reduced DNA-binding and transactivating activities

AU - Trecca, Dino

AU - Guerrini, Luisa

AU - Fracchiolla, Nicola Stefano

AU - Pomati, Mauro

AU - Baldini, Luca

AU - Maiolo, Anna Teresa

AU - Neri, Antonino

PY - 1997

Y1 - 1997

N2 - Alterations of NF-κB family members have been found to be associated with various forms of lymphoid malignancies. In order to determine whether alterations of the RelA gene are involved in lymphomagenesis, we analysed a large and representative panel (200 cases) of such tumors. Southern blot analysis did not reveal any rearrangements or locus amplification, suggesting that structural alterations of the RelA gene may represent rare events in lymphoid neoplasia. By means of PCR-SSCP analysis, we were able to identify a single point mutation leading to amino acid substitution (codon 494, Glu-Asp) in the transactivating (TA) domain in one case of multiple myeloma. The mutated allele was expressed in the pathological bone marrow sample but not in the peripheral blood cells of the patient. We demonstrate that the RelA protein carrying this specific mutation (called RelA(494D)) has less transactivating ability than the normal RelA protein. Interestingly, the mutated protein has a lower affinity for κB binding sites both as a homodimer or in association with the NFKB1/p50 subunit. Transfection experiments using a Gal4-RelA(494D) fusion protein indicated that the mutation does not alter the intrinsic transactivating ability of the TA domain of RelA. Furthermore, in vitro translated RelA(494D) is able to dimerize efficiently with other NF-κB members, such as p50, cREL and IκBα. Our data therefore suggest that this mutation may alter the specific structural conformation needed for the DNA interaction of RelA, and provide insights into the amino acid sequences involved in mediating the biological activities of RelA.

AB - Alterations of NF-κB family members have been found to be associated with various forms of lymphoid malignancies. In order to determine whether alterations of the RelA gene are involved in lymphomagenesis, we analysed a large and representative panel (200 cases) of such tumors. Southern blot analysis did not reveal any rearrangements or locus amplification, suggesting that structural alterations of the RelA gene may represent rare events in lymphoid neoplasia. By means of PCR-SSCP analysis, we were able to identify a single point mutation leading to amino acid substitution (codon 494, Glu-Asp) in the transactivating (TA) domain in one case of multiple myeloma. The mutated allele was expressed in the pathological bone marrow sample but not in the peripheral blood cells of the patient. We demonstrate that the RelA protein carrying this specific mutation (called RelA(494D)) has less transactivating ability than the normal RelA protein. Interestingly, the mutated protein has a lower affinity for κB binding sites both as a homodimer or in association with the NFKB1/p50 subunit. Transfection experiments using a Gal4-RelA(494D) fusion protein indicated that the mutation does not alter the intrinsic transactivating ability of the TA domain of RelA. Furthermore, in vitro translated RelA(494D) is able to dimerize efficiently with other NF-κB members, such as p50, cREL and IκBα. Our data therefore suggest that this mutation may alter the specific structural conformation needed for the DNA interaction of RelA, and provide insights into the amino acid sequences involved in mediating the biological activities of RelA.

KW - Lymphoid malignancies

KW - NF-κB

KW - RelA

KW - Transcriptional activity

UR - http://www.scopus.com/inward/record.url?scp=0031039111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031039111&partnerID=8YFLogxK

M3 - Article

C2 - 9047386

AN - SCOPUS:0031039111

VL - 14

SP - 791

EP - 799

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 7

ER -